|
|
| A Pharma Perspective on Metabolomics: |
|
| Opportunities & Realities |
|
|
|
|
|
|
|
|
| John Haselden PhD |
||||||
| Director, Investigative Preclinical Toxicology |
||||||
| GlaxoSmithKline R&D, UK |
||||||
| Metabolomics Society Meeting |
||||||
| Harvard Medical School Conference Center, Boston |
||||||
| 28th June 2006 |
||||||